Red Biotechnology Market By Application (Biopharmaceutical Manufacture, Pharmacogenomics, Gene Therapy, and Genetic Testing), By End-user (Biopharmaceutical Business, Research Organizations, CMOs & CROs, and Others), and By Region - Market Trends, Analysis, and Forecast till 2029

Report Code: PMI435320 | Publish Date: March 2024 | No. of Pages: 170

Global Red Biotechnology Market Companies

  • Pfizer, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc.
  • CELGENE CORPORATION
  • Glead Sciences, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited

Recent News:

  • In June 2024, Bio-Rad Launches Four New Anti-idiotypic Antibodies. Anti-idiotypic antibodies for the medications atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ocrelizumab (Ocrevus) are now part of Bio-Rad's expanded line of anti-biotherapeutic antibodies. Furthermore, the biotherapeutic antibody range of the life science research and clinical diagnostics product specialist has been introduced, which may be utilised in bioanalysis, for anti-monomethyl auristatin E (MMAE).